Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE